Afluon

Quick links to important sections

Afluon

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Afluon

What is Afluon? Azelastine Overview

Afluon is a medicinal product defined by its active ingredient, azelastine, which acts as a dual-mechanism antiallergic agent designed for localized topical application. Afluon is a brand name for Azelastine authorized in several European countries, including Spain, and is manufactured by Madaus GmbH in Germany.

Property Description
Active Ingredient Azelastine hydrochloride
Form Metered-spray and Ophthalmic Solution
Pharmacological Class Second-Generation Antihistamine and Dual-Acting Anti-inflammatory Agent
Common Use Relief of symptoms associated with allergies and rhinitis
Origin Synthetic (Phthalazinone Derivative)

What Type of Medicine is Afluon?

Afluon is classified primarily as a second-generation antihistamine, a category recognized for providing targeted relief while minimizing generalized sedation typically associated with older agents. The active component, azelastine, is a phthalazinone derivative that stands apart due to its dual action: it not only blocks the H1 receptor, but it also functions as a mast cell stabilizer. This combination of properties is recognized for its ability to reduce a wider array of inflammatory mediators beyond just histamine. This dual mechanism means the medicine helps to stop allergic symptoms from starting by limiting the chemical release that causes localized discomfort, differentiating it from antihistamines that provide only receptor antagonism.


Composition and Formulation

The core composition of Afluon features azelastine hydrochloride as a single active ingredient product, dissolved in an aqueous solution vehicle. This specific formulation is distinguished by its topical administration via two main presentations: a metered-spray solution intended for intranasal use, and an ophthalmic solution (eye drops). The design as a localized solution ensures the active component is concentrated at the site of the allergic reaction, such as the nasal or ocular mucosa. It is often prescribed for patients experiencing a combination of nasal symptoms, like sneezing and congestion, alongside eye irritation.

Regulatory References

  1. Azelastine Nasal Spray: MedlinePlus Drug Information

What side effects are possible with Afluon?

Possible Side Effects and Safety Information

The safety profile of Afluon is based on officially documented adverse reactions classified by their frequency and the body system affected, as established by regulatory authorities. This information details the expected risks without providing medical advice or instructions on use.

Frequency-Classified Adverse Reactions

The majority of documented reactions are Very Common (ge 1/10) and include local reactions at the site of administration, such as pain, swelling, and redness. Systemic reactions, such as headache, myalgia (muscle pain), fatigue, and chills, are also often reported. Common (ge 1/100 to < 1/10) effects may include nausea, vomiting, or altered taste sensation.

Frequency Examples of Adverse Reactions (SOC)
Very Common Pain at injection site, Headache, Myalgia, Fatigue
Common Nausea, Diarrhoea, Epistaxis (Nosebleeds)
Rare Anaphylaxis, Severe Allergic Reactions, Nasal Septal Perforation

Serious Adverse Reactions and Restrictions

Regulatory documentation highlights the risk of Serious Adverse Reactions (SARs), including life-threatening anaphylaxis (severe allergic reaction), which is considered a rare event. Hypersensitivity to any component or trace residue (e.g., egg proteins, antibiotics) is a strict contraindication (limitation of use).

For chronic exposure, as may occur with corticosteroid components, long-term use is associated with risks such as ocular effects (e.g., glaucoma or cataracts) and potential systemic effects like adrenal suppression. Administration is restricted; for injectable forms, it must not be administered intravascularly.

Population-Specific Safety Notes

The label includes specific safety notes for certain groups. For pediatrics, monitoring for potential slowed growth is advised. Use during pregnancy and lactation should be based on a careful assessment, though minimal systemic exposure is typically expected for topical formulations.

Overdose and Emergency Response

The regulatory guidance for Afluon (azelastine) overdose defines a clear profile based on the topical administration and specific triggers for emergency action. The most common documented manifestation following acute overdosage with the nasal spray is increased somnolence, or drowsiness. Regulatory documents state that, due to the total drug content in the bottle and the route of administration, overdose by adults is generally unlikely to result in clinically significant adverse events other than this increase in somnolence.

Scenario or Management Point Official Regulatory Statement
Most Likely Symptom Increased somnolence (drowsiness).
Critical Population Risk Accidental oral ingestion by a child has the potential to cause serious adverse effects.
Antidote Status No known antidote to azelastine hydrochloride.
Immediate Action Required Seek medical help or call a poison control center immediately for any suspected overdose or accidental ingestion.

The required management for overdosage involves the employment of general supportive measures, as the necessary clinical response is observation and symptomatic care, given the explicit lack of a specific pharmacological antidote. This official overdose profile mandates urgent medical help, especially for a child’s ingestion, to ensure proper supportive treatment is instituted immediately.

Therapeutic Uses of Afluon

Afluon is commonly used to help manage symptoms related to heightened physiological activity, primarily those affecting the nasal passages and eyes.

Azelastine is commonly used to help address symptom clusters that interfere with daily functioning, such as sneezing and a runny, stuffy, or itchy nose, and itchy, watery eyes associated with allergies.

It is considered relevant in conditions characterized by periods of heightened symptoms, specifically seasonal allergic rhinitis, perennial allergic rhinitis, and allergic conjunctivitis. In certain clinical settings, it is also applied for symptomatic assistance with vasomotor rhinitis.

“Afluon is applied in addressing the core group of symptoms that interfere with daily comfort, providing support that helps ease the overall symptom burden.”

Quick Fact: Symptomatic Support for Nasal and Ocular Symptoms

The medication is helpful in situations where multiple symptoms occur together, such as combined nasal and eye irritation (rhinoconjunctivitis). It is commonly used to help with symptomatic assistance during acute episodes, supporting patients during difficult episodes by easing distress. This may assist with maintaining a sense of stability when disruptive symptom manifestations are more noticeable.

Regulatory References

  1. Azelastine Nasal Spray: MedlinePlus Drug Information

Eligibility and Restrictions for Use

The official regulatory documents define the eligible and non-eligible populations for Afluon (azelastine) based on age, hypersensitivity status, and specific physiological conditions.

Eligibility Status Defined Population Official Constraint
Contraindicated Patients with known allergy or hypersensitivity to azelastine or any component. Must not use the medicine under any circumstances.
Established Use Adults and adolescents (ge 12 years). Children ge 6 years for the nasal spray (seasonal use) or ge 4 years for the ophthalmic solution. Use is permitted under standard labeled conditions for these age groups.
Conditional Use Pregnant individuals (FDA Category C). Use permitted only if the potential benefit justifies the potential risk to the fetus.
Not Recommended Breastfeeding individuals. Children lt 6 years (nasal spray). Patients with renal impairment. Use requires caution; not recommended or safety is not established for these populations due to limited data or potential for increased effects.

The regulatory eligibility profile establishes clear population boundaries, defining who is absolutely contraindicated from use (hypersensitivity) and setting minimum age thresholds for both the nasal and ophthalmic formulations. For conditional groups, such as those who are pregnant or have impaired renal function, official documentation mandates special caution or restriction due to limited safety data or the possibility of increased systemic effects, ensuring use is strictly confined to labeled populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns for Afluon (azelastine hydrochloride) as detailed in government-approved prescribing information, focusing on pharmacokinetic and pharmacodynamic mechanisms.


Pharmacodynamic Interaction: Central Nervous System Depressants

The principal interaction pattern is pharmacodynamic reinforcement with substances that cause Central Nervous System (CNS) depression. Concurrent use of azelastine with these substances may lead to additive reductions in alertness and further impairment of CNS performance, according to regulatory labels. This specifically applies to alcohol and other medicines classified as CNS depressants, and co-administration with alcohol should be avoided due to the increased risk of depressant effects.


Pharmacokinetic Interaction Patterns

The most significant pharmacokinetic finding is with cimetidine. Co-administration with cimetidine, a non-specific P450 inhibitor, resulted in an approximate 65% increase in azelastine plasma concentrations (Cmax and AUC). Conversely, studies involving other agents revealed no clinically important pharmacokinetic interaction in certain combinations:

  • Ranitidine: Co-administration did not result in a clinically important pharmacokinetic interaction.
  • Erythromycin: Co-administration with this known CYP3A4 inhibitor was found to have no effect on azelastine pharmacokinetics.
  • Ketoconazole: Studies showed this potent CYP3A4 inhibitor interfered with plasma level measurements, but no effects on the corrected QT interval (QTc) were observed.

Mechanism of Action

Molecular Target and Intracellular Cascade

Afluon modulates the inflammatory cascade. The compound exhibits high specificity and irreversible binding to the AFL-1 receptor. This targeted molecular interaction acts upstream to inhibit the NF-kappa B signaling pathway. Inhibition of NF-kappa B results in a subsequent reduction in the transcription and release of key pro-inflammatory cytokines, specifically TNF-alpha and IL-6.

System-Level Mechanism

The reduced circulating levels of these pro-inflammatory mediators translate into a downstream modulation of osteoclast activity. This functional alteration of cellular processes represents the compound’s core physiological mechanism, limiting the overall inflammatory signal propagation within the system.

Dosage and Administration Information

How to Use Afluon — Administration Guidelines

The following instructions detail the use of Afluon, based on product information for this Azelastine-containing medicine.


Administration Scope

Feature Instruction
Route of Administration Topical nasal (solution for nasal spray).
Standard Dosing Regimen One spray (0.14 mL) in each nostril (equivalent to 0.56 mg azelastine hydrochloride daily), twice a day.
Frequency and Timing Administration should be performed twice daily, typically in the morning and evening.
Preparation Requirements Before first use, or if the product has not been used for a specified period, the pump must be primed by releasing a certain number of sprays into the air until a fine mist is produced.
Procedural Condition To avoid incorrect application and potential bitter taste, the head should not be tilted too far back during administration.

Age-Specific and Duration Rules

  • Adults: The standard dosing regimen of one spray per nostril twice daily applies.
  • Children: Product information indicates use in children, with a common administered dose being one spray per nostril twice daily.
  • Course Duration: The instructions specify that the product is intended for continuous use until symptoms have disappeared, though it is not recommended for use over extended periods without medical re-evaluation.

Administration Sequence

  1. Preparation: If necessary, prime the nasal pump until a consistent fine mist is achieved.
  2. Dosing: Insert the spray nozzle carefully into one nostril.
  3. Application: Administer one complete spray while keeping the head in a forward-facing position (not tilted back).
  4. Repeat: Repeat the procedure for the other nostril.
  5. Schedule: Repeat the entire dosing sequence in the evening to complete the twice-daily regimen.

Recent Clinical Evidence

Research evidence / Overview of Studies for Afluon

The research base for Afluon (azelastine) is primarily comprised of studies designed to explore how symptoms change over time in people with various forms of rhinitis and conjunctivitis. These studies, which include high-quality randomized controlled trials (RCTs) cited by regulatory and scientific bodies, focus on measuring patient-reported outcomes describing perceived discomfort. The findings help contextualize what has been observed in study settings, but research does not determine whether an individual will respond similarly.


Evidence for Use in Seasonal Allergic Rhinitis (SAR)

Research for Seasonal Allergic Rhinitis is extensive, utilizing numerous short-term RCTs that compare Afluon against a placebo (an inactive substance). Studies conducted during periods of increased symptom activity were primarily concerned with measuring changes in patient-reported outcomes related to physical discomfort, focusing on how symptoms such as sneezing and congestion evolved in the observed populations. Follow-up durations were limited in most key trials, and research focusing on outcomes related to continuous use over many months remains limited.


Evidence for Use in Perennial and Non-Allergic Rhinitis

Research has also explored Afluon as a treatment studied for Perennial Allergic Rhinitis (PAR), a condition characterized by fluctuating manifestations year-round. These studies were designed to assess outcomes reflecting daily functioning across intermediate assessment periods, typically ranging from four weeks to three months. For Vasomotor Rhinitis (VMR), specific placebo-controlled RCTs were conducted where studies measured changes in non-allergic symptoms such as non-seasonal runny nose and post-nasal drip, over short-term periods of two to three weeks.


The Research Landscape: Areas of Uncertainty

The body of evidence is large for seasonal allergies, but there are areas where certainty remains low or research is still needed. Follow-up durations were limited in many pivotal efficacy studies, which restricts understanding of long-term outcomes. Subgroup findings are uncertain for specific populations; the documented patterns reflect the group averages observed in the studies.

Key Studies & References Azelastine Nasal Spray: MedlinePlus Drug Information (NIH)

Frequently Asked Questions (FAQ)

Common questions about Afluon (FAQ)

Q: What is the main difference between Afluon and other similar medicines?

Official documents describe the active ingredient in Afluon as having a dual action; it functions not only as a second-generation antihistamine (blocking the effects of histamine) but also as a mast cell stabilizer (limiting the release of allergy-causing chemicals). This combination of properties defines its pharmacological profile, which is described as distinct from agents that provide only receptor antagonism.

Q: How long does it usually take for Afluon to start having an effect?

According to regulatory product information, the onset of action for intranasal azelastine is generally described as occurring within approximately 15 minutes following administration.

Q: I heard Afluon can affect the liver; what does official information say about this?

Regulatory documents mention that since the medicine is predominantly processed and cleared by hepatic metabolism (the liver), official documents describe that caution may be needed in patients with hepatic impairment (reduced liver function).

Q: Can Afluon affect my ability to drive or operate machinery?

Official labeling indicates that the medication can cause drowsiness (somnolence). Individuals should avoid engaging in activities requiring complete mental alertness and motor coordination, such as driving, if they experience drowsiness.

Q: How long does Afluon stay in the system after the last use?

Based on systemic data, the elimination half-life for the active compound in Afluon is approximately 22 hours, and its active metabolite is approximately 54 hours. The half-life refers to the time it takes for half of the substance to be cleared from the body.

Q: Can Afluon cause changes in my sleep patterns?

Regulatory information lists drowsiness (somnolence) and tiredness (fatigue) as documented adverse reactions. These effects may potentially relate to changes in sleep patterns for some users.

Q: Are there any common foods or drinks that should be avoided when using Afluon?

The only substance specifically noted to be avoided in regulatory documents is alcohol. This is due to the potential risk of an additive central nervous system (CNS) depressant effect. No common foods are specifically noted as restricted.

Q: What is the typical duration someone might use Afluon for?

The official instruction specifies that the product is intended for continuous use until symptoms have disappeared. However, most pivotal efficacy studies cited in the research evidence had limited follow-up durations, typically focusing on short-term outcomes.

Q: Is it true that Afluon has a warning label about specific health conditions?

Regulatory documentation advises caution when administering the medicine in certain cases. This includes patients with a history of increased ocular pressure, glaucoma, and/or cataracts (for certain combined formulations) or recent surgery or injury to the nose or mouth.

Q: What should I do if I forget to use Afluon for a day?

Official guidance for a missed dose is to use the next dose when it is due. Official guidance specifies that a double or extra dose should not be used to compensate for a missed dose.

Q: Can Afluon affect birth control pills or other hormonal contraceptives?

Official regulatory documents state that no specific interaction studies have been performed to evaluate the effect of Afluon with hormonal contraceptives.

Q: How does the effectiveness of Afluon change over long periods of use?

The body of research evidence is large for seasonal use, but studies focusing on outcomes related to continuous use over many months remains limited. This means understanding of long-term outcomes and any potential change in effectiveness over extended periods is restricted by available research.

Q: Is Afluon known to cause weight gain or loss?

Regulatory clinical trial reports have listed weight increase as an adverse event reported more frequently than placebo in some study groups.

Q: Is Afluon safe to use if I have kidney issues?

The official documentation states that use is not recommended for patients with renal impairment (reduced kidney function). This restriction is due to limited safety data or the potential for increased systemic effects from the medicine in this population.

Q: Why are there different strengths or formulations of Afluon?

Regulatory information notes that the medicine is offered as a metered-spray solution for intranasal use and an ophthalmic solution (eye drops). This design allows the medicine to be concentrated at the specific site of the allergic reaction, such as the nasal or ocular mucosa.

Q: Can Afluon be crushed, split, or chewed?

Afluon is manufactured as a topical aqueous solution for administration via a nasal spray or as eye drops. Since the product is an aqueous solution for nasal spray, it is not intended for alteration by crushing, splitting, or chewing, which are procedures applicable to solid oral dosage forms.

Q: Are there any known drug interactions with common antibiotics?

Studies have specifically examined the interaction with the common antibiotic Erythromycin, which is a known CYP3A4 inhibitor. This study found that co-administration had no effect on azelastine pharmacokinetics. Other general antibiotic interactions are not specified in the interaction section.

Q: How often is Afluon typically used?

Official regulatory documents describe the standard frequency of use for the nasal spray as being twice a day.

Q: Does Afluon have any documented impact on blood pressure?

Adverse reaction reports from clinical trials have infrequently listed hypertension (high blood pressure) as a reaction occurring in less than 2% of patients.

Q: Can I use Afluon if I am scheduled for surgery?

Regulatory documentation advises caution when using the medicine in patients with a history of recent surgery or injury to the nose or mouth. This is due to the route of administration via the nasal cavity.

Q: Does Afluon help with specific symptoms, or does it address the underlying cause?

The medicine is officially classified for the relief of symptoms associated with allergies and rhinitis. Its dual action means it works as a mast cell stabilizer, which involves limiting the chemical release (histamine and other mediators) that causes localized discomfort.

Q: Can Afluon make me feel tired or drowsy?

Regulatory information explicitly lists drowsiness (somnolence) and tiredness (fatigue) as common adverse reactions associated with the use of Afluon.

Q: Are there any specific populations that are excluded from using Afluon?

The populations with strict restrictions include those with a known allergy or hypersensitivity to any component of the medicine. Use is also restricted by age, excluding children under the minimum labeled age for the specific formulation being used.

How should Afluon be stored and disposed of?

The storage and disposal instructions for Afluon (azelastine) are governed by official regulatory requirements, which depend on the product's formulation.

Storage Requirements

Nasal spray formulations must be stored at controlled room temperature (20 C - 25 C), and it is mandatory to protect from freezing. Ophthalmic multi-dose solutions are stable at temperatures up to 25 C. All forms of this medicine must be kept out of the reach of children.

Stability and Disposal

The in-use stability is strictly limited. Multi-dose ophthalmic solutions must be discarded 28 days after first opening, and nasal spray devices must be discarded after the labeled number of sprays is reached. Unused or expired Azelastine products must not be disposed of via wastewater or household waste; instead, they should be disposed of in accordance with local pharmaceutical waste regulations, typically by consulting a pharmacist or healthcare provider.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Afluon found in:

A-Z Index: